Hydroxyapatite Chromatography Purifying Erythropoietin
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing and purifying recombinant erythropoietin are complex and inefficient, particularly in achieving high purity and desired isoform distribution, with challenges in removing host cell proteins and optimizing glycosylation profiles.
Innovation Solution
A method involving multiple chromatography steps, including hydroxyapatite chromatography, affinity chromatography, hydrophobic interaction chromatography, and reversed phase chromatography, with specific buffer conditions and elution strategies to achieve high purity and controlled isoform distribution of erythropoietin, while also depleting host cell proteins and optimizing glycosylation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If multiple chromatography steps are used to achieve high purity erythropoietin, then purity is improved, but process complexity increases
Solution Approach 1:
The patent combines multiple chromatography techniques (affinity chromatography, hydrophobic interaction chromatography, and hydroxyapatite chromatography) into a sequential purification process. Each chromatography step targets specific impurities: affinity chromatography removes host cell proteins, hydrophobic interaction chromatography purifies erythropoietin variants, and hydroxyapatite chromatography achieves final high purity. This merging of multiple separation mechanisms in sequence resolves the contradiction by achieving >99.3% purity through integrated multi-step chromatography.
Solution Approach 2:
The purification process is segmented into distinct chromatography stages, each with specific buffer conditions and elution strategies. The process divides purification into: (1) affinity chromatography step with specific ligands, (2) hydrophobic interaction chromatography with alcohol gradients, and (3) hydroxyapatite chromatography with calcium phosphate buffers. This segmentation allows each step to address specific purification challenges independently, managing overall process complexity through modular design.
2Manufacturing precision
If hydroxyapatite chromatography is used with specific buffer conditions, then isoform distribution is improved, but process time increases
Solution Approach 1:
The patent utilizes parameter changes in buffer composition to control erythropoietin isoform distribution during hydroxyapatite chromatography. Specific buffer conditions including calcium ion concentrations (5 mM), TRIS-HCl pH (6.9 ± 0.2), and the presence of 2-propanol (9% v/v) are optimized to selectively elute different glycosylated isoforms. The elution strategy employs controlled changes in calcium concentration and buffer composition to achieve desired isoform profiles, balancing purification precision with process efficiency.
Solution Approach 2:
The hydroxyapatite chromatography step is positioned after affinity and hydrophobic interaction chromatography steps have already performed preliminary purification. This preliminary action removes bulk impurities and concentrates erythropoietin, allowing the hydroxyapatite step to focus specifically on isoform distribution control rather than general purification, thereby reducing overall process time while maintaining isoform precision.
3Manufacturing precision
If affinity chromatography is used to remove host cell proteins, then purity is improved, but host cell protein depletion efficiency decreases
Solution Approach 1:
The patent employs affinity chromatography with specific ligands that act as intermediaries to selectively bind and remove host cell proteins from the erythropoietin solution. The affinity matrix serves as a mediator that captures host cell protein contaminants while allowing erythropoietin to pass through or be subsequently recovered. This intermediary approach enables efficient host cell protein depletion without directly treating the erythropoietin, maintaining high purity while improving depletion efficiency through the mediating affinity interaction.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method achieves high purity (>99.3%) erythropoietin with improved isoform distribution and reduced host cell protein contamination, enhancing the therapeutic efficacy of the recombinant erythropoietin.
Implementation Method 1
a stationary phase containing hydroxyapatite which has been equilibrated with a solution containing Calcium-ions at the same concentration of 5 mM
Implementation Method 2
bringing an erythropoietin containing solution into contact with a stationary phase containing ceramic hydroxyapatite
Data Source
Figure 1
Figure 2
Figure 3
AI summary
In the present invention a method for purifying erythropoietin comprising at least one chromatography step using a stationary phase containing hydroxyapatite is reported. The method comprises the following steps i) the erythropoietin in a solution containing Calcium-ions is brought into contact with a stationary phase containing hydroxyapatite equilibrated with a solution containing Calcium-ions and namely under conditions under which the erythropoietin binds to the stationary phase containing hydroxyapatite, ii) a solution is passed over the stationary phase containing hydroxyapatite from i) which contains less Calcium-ions than the previous solution and the erythropoietin is not detached from stationary phase containing hydroxyapatite, and iii) a further solution which contains less than 0.5 mM Calcium-ions is passed over the stationary phase containing hydroxyapatite from ii) whereby the erythropoietin is detached from the stationary phase containing hydroxyapatite.